FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
2019 · eLife · 133 citations
https://doi.org/10.7554/elife.47327
M
Marjaana Ojalill
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
35
Papers
394
Citations
8
h-index
8
i10-index
Marjaana Ojalill is an academic researcher from Åbo Akademi University. The author has contributed to research in topics: Cell Adhesion Molecules Research & Ovarian cancer diagnosis and treatment & Immunotherapy and Immune Responses. The author has an h-index of 8, co-authored 30 publications.
ORCID: 0000-0003-3181-6742Papers by this author
worksTumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis
2022 · Proceedings of the National Academy of Sciences · 70 citations
https://doi.org/10.1073/pnas.2117065119
Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities
2024 · Journal of Cell Science · 19 citations
https://doi.org/10.1242/jcs.261723
Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024 · Cancer Research Communications · 7 citations
https://doi.org/10.1158/2767-9764.crc-24-0382
Inducible FAK loss but not FAK inhibition in endothelial cells of PYK2-null mice activates p53 tumor suppressor to prevent tumor growth
2025 · Molecular Biology of the Cell · 3 citations
https://doi.org/10.1091/mbc.e24-12-0562
RAS/RAF/MEK mutated high-grade serous ovarian cancer susceptible to Raf inhibition in vitro but not in vivo
2024 · Gynecologic Oncology · 0 citations
https://doi.org/10.1016/j.ygyno.2024.07.215
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat